Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab - Eckstein, Markus; Erben, Philipp; Kriegmair, Maximilian; Worst, Thomas; Weis, Cleo-Aron Thias (European journal of cancer, 2019)
Gesehen am 18.07.2019